Risk of fetal or neonatal death or neonatal intensive care unit admission associated with gadolinium magnetic resonance imaging exposure during pregnancy
Almut G. Winterstein(University of Florida), Sonja A. Rasmussen(Johns Hopkins University), Ira Krefting(United States Food and Drug Administration), Nicole E. Smolinski(University of Florida), Steven T. Bird(United States Food and Drug Administration), Leyla Şahin, Thuy Nhu Thai(Harvard University), Sabina O. Nduaguba(Center for Drug Evaluation and Research), Xi Wang(University of Florida), Kate Gelperin(United States Food and Drug Administration)
Cited by 42
Related Papers
H1N1 2009 influenza virus infection during pregnancy in the USA
|The Lancet|2009|1.4k
Guidelines for case classification for the national birth defects prevention study
|Birth Defects Research Part A Clinical and Molecular Teratology|2003|579
Reviewing the evidence for mycophenolate mofetil as a new teratogen: Case report and review of the literature
|American Journal of Medical Genetics Part A|2009|223
Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis
|Canadian Medical Association Journal|2012|120
Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers
|American Journal of Obstetrics and Gynecology|2013|118